These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 20981086)
1. Drug development: Longer-lived proteins. Hubbell JA Nature; 2010 Oct; 467(7319):1051-2. PubMed ID: 20981086 [No Abstract] [Full Text] [Related]
2. PharmGKB summary: peginterferon-α pathway. Shuldiner SR; Gong L; Muir AJ; Altman RB; Klein TE Pharmacogenet Genomics; 2015 Sep; 25(9):465-74. PubMed ID: 26111151 [No Abstract] [Full Text] [Related]
3. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy. Hu J; Wang G; Zhao W; Gao W J Control Release; 2016 Sep; 237():71-7. PubMed ID: 27393654 [TBL] [Abstract][Full Text] [Related]
4. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. Chan LJ; Feeney OM; Leong NJ; McLeod VM; Porter CJH; Williams CC; Kaminskas LM Biomacromolecules; 2017 Sep; 18(9):2866-2875. PubMed ID: 28731677 [TBL] [Abstract][Full Text] [Related]
5. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859 [TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of pegylated proteins in oncology. Crawford J Cancer Treat Rev; 2002 Apr; 28 Suppl A():1-2. PubMed ID: 12173406 [No Abstract] [Full Text] [Related]
7. [Pegylated interferons: preliminary review of their pharmacokinetic characteristics]. Azanza Perea JR Rev Clin Esp; 2001 Apr; 201(4):205-12. PubMed ID: 11447908 [No Abstract] [Full Text] [Related]
8. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C. Quinn D; Kuchler E; Deming P; Arora S Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752 [No Abstract] [Full Text] [Related]